Publicaciones en las que colabora con Ruth Vera García (12)

2021

  1. Controversies in the treatment of RAS wild-type metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839

  2. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  3. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

    ESMO open, Vol. 6, Núm. 4, pp. 100215

2019

  1. Correction to: Recommendations for follow‑up of colorectal cancer survivors (Clinical and Translational Oncology, (2019), 21, 10, (1302-1311), 10.1007/s12094-019-02059-1)

    Clinical and Translational Oncology

  2. Recommendations for follow-up of colorectal cancer survivors

    Clinical and Translational Oncology, Vol. 21, Núm. 10, pp. 1302-1311

  3. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 46-54

2018

  1. New wind for the Spanish Federation of Scientific Oncological Societies (FESEO)

    Clinical and Translational Oncology

2017

  1. SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 135-148

2016

  1. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1172-1178

  2. SEOM Clinical Guideline of localized rectal cancer (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1163-1171

2015

  1. Current controversies in the management of metastatic colorectal cancer

    Cancer Chemotherapy and Pharmacology, Vol. 76, Núm. 4, pp. 659-677

2013

  1. Bevacizumab plus chemotherapy continued beyond first progression in patients withmetastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

    Annals of Oncology, Vol. 24, Núm. 9, pp. 2342-2349